VivoSeq
Ophthalmology

Ocular Pain

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Ocular pain is an early-stage landscape with 4 programs across 2 companies. The most active players are EyePoint Pharmaceuticals, Inc., Roche. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

71/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

EyePoint Pharmaceuticals, Inc.

1 program

Phase 3Roche logo

Roche

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Completed5 · 63%
Withdrawn2 · 25%
Not yet recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy
Not yet recruiting·BBausch & Lomb Incorporated·Phase 2·NCT07412496·123 enrolled
Nepafenac Compared to Placebo for Ocular Pain and Inflammation
Completed·AAlcon Research·Phase 3·NCT01426854·260 enrolled
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
Completed·OOcular Therapeutix, Inc.·Phase 3·NCT04539548·65 enrolled
Topical Naloxone to Diagnose Ocular Pain
Completed·—·Phase 1·NCT04454281·1 enrolled
Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
Completed·—·Phase 1/2·NCT01776658·60 enrolled
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
Completed·—·Phase 2·NCT02455999·66 enrolled
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
Withdrawn·EEyePoint Pharmaceuticals, Inc.·Phase 3·NCT05550350
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
Withdrawn·EEyePoint Pharmaceuticals, Inc.·Phase 3·NCT05550363

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)